A Narrative Review of Pharmacologic Treatments for <scp>COVID</scp>‐19: Safety Considerations and Ototoxicity

Little, C. C.; Cosetti, Maura K.

doi:10.1002/lary.29424

Cited by 21 publications

(33 citation statements)

References 72 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 Another antiviral agent, ribavirin, is known to cause severe SNHL if prescribed alongside interferon, even if the data about ototoxic effects of ribavirin alone are scarce. 34 Specific references on the history of exposure to ototoxic drugs were reported in 4 over 20 patients and these cases are included in this review. 7,10,14,24 All patients received hydroxychloroquine alone or in association to other established potential ototoxic drugs, such as azithromycin or furosemide; a clear correlation between their symptoms and the adverse effects of these medications was not established.…”

Section: Ototoxicity Of Covid-19 Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 (COVID-19) and audio-vestibular disorders

Fancello

Hatzopoulos

Corazzi

et al. 2021

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

To describe the audio-vestibular disorders related to the newly SARS-CoV-2 infection, including the possible ototoxicity side-effects related to the use of drugs included in the SARS-CoV-2 treatment protocols. A systematic review was performed according to the PRISMA protocol. The Medline and Embase databases were searched from March 1, 2020 to April 9, 2021. Initially the search yielded 400 manuscripts, which were reduced to 15, upon the application of inclusion criteria. Sensorineural hearing loss (SNHL) is the most frequent audio-vestibular symptom described, occurring alone or in association with tinnitus and vertigo. The etiopathogenesis of the inner ear disorders related to COVID-19 infection is still poorly understood. The number of reports of COVID-19 infections associated to audio-vestibular disorders is increasing; even if the quality of the studies available is often insufficient, audio-vestibular disorders should be considered as possible manifestations to be included among the symptoms of this infection.

show abstract

Section: Ototoxicity Of Covid-19 Treatmentsmentioning

confidence: 99%

“…Another antiviral agent, ribavirin, is known to cause severe SNHL if prescribed alongside interferon, even if the data about ototoxic effects of ribavirin alone are scarce. 34 …”

Section: Ototoxicity Of Covid-19 Treatmentsmentioning

confidence: 99%

SARS-CoV-2 (COVID-19) and audio-vestibular disorders

Fancello

Hatzopoulos

Corazzi

et al. 2021

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…

In Reply:We would like to thank Narozny et al for their interest in our publication "A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity" and their insightful comments regarding the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and sudden sensorineural hearing loss (SSNHL). 1,2 We agree with the authors that any COVID-19 patients experiencing SSNHL should be considered high-risk and receive urgent audiologic evaluation.The growing body of literature regarding the incidence of SSNHL in COVID-19 patients, whether it be through exposure to ototoxic agents or due to SARS-CoV-2 infection itself, highlights the importance for all members of a patient's care team to maintain vigilance regarding the symptoms of SSNHL. Quick recognition and diagnosis of SSNHL, regardless of exposure to ototoxic agents, may be critical to recovery of audiologic function, audio-vestibular sequelae and improve quality of life.

…”

mentioning

confidence: 60%

“…We would like to thank Narozny et al for their interest in our publication "A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity" and their insightful comments regarding the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and sudden sensorineural hearing loss (SSNHL). 1,2 We agree with the authors that any COVID-19 patients experiencing SSNHL should be considered high-risk and receive urgent audiologic evaluation.…”

mentioning

confidence: 60%

In Response to The Challenges of Pharmacotherapy of SARS‐CoV‐2 Infection in Patients with Sudden Sensorineural Hearing Loss Due to COVID‐19

Little

Cosetti

2021

The Laryngoscope

Self Cite

View full text Add to dashboard Cite

In Reply:We would like to thank Narozny et al. for their interest in our publication "A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity" and their insightful comments regarding the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and sudden sensorineural hearing loss (SSNHL). 1,2 We agree with the authors that any COVID-19 patients experiencing SSNHL should be considered high-risk and receive urgent audiologic evaluation.The growing body of literature regarding the incidence of SSNHL in COVID-19 patients, whether it be through exposure to ototoxic agents or due to SARS-CoV-2 infection itself, highlights the importance for all members of a patient's care team to maintain vigilance regarding the symptoms of SSNHL. Quick recognition and diagnosis of SSNHL, regardless of exposure to ototoxic agents, may be critical to recovery of audiologic function, audio-vestibular sequelae and improve quality of life. 3 Studies have demonstrated that early treatment of hearing loss with corticosteroids results in significantly higher rates of complete hearing recovery than control groups without intervention. 3,4 Current guidelines emphasize the importance of initiating treatment for hearing loss within 7 days of symptom onset. 3 Our understanding of the immediate and long-term consequences of SARS-CoV-2 infection is constantly evolving. A recent study found evidence of decreased transient evoked otoacoustic emissions amplitudes and significantly lowered high-frequency pure tone audiometry thresholds among asymptomatic patients with PCRconfirmed SARS-CoV-2 infection, suggesting evidence of cochlear damage even in minor cases of While evidence regarding the long-term impact of COVID-19 on audiovestibular function is still being compiled, it is imperative for all healthcare providers to remain aware of the potential for audiologic dysfunction in COVID-19 patients and refer for prompt audiologic evaluation. Persistent vigilance on audiovestibular symptoms is needed as we embark on the exciting-and imperative -period of mass vaccination.

show abstract

“…

We read with colossal interest the manuscript of Little et al entitled "A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity." 1 The authors concluded that among those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-risk patient groups treated with ototoxic drugs should be given special attention, such as the elderly and hearing impaired. We agree with the authors of the publication.

…”

mentioning

confidence: 99%